Structure Therapeutics, Inc. Sponsored ADR (GPCR) Price & Analysis

Compare

1,047 Followers

GPCR Stock Chart & Stats

Day’s Range― - ―

52-Week Range$13.22 - $45.37

Previous CloseN/A

Volume219.80K

Average Volume (3M)1.12M

Market Cap

$1.16B

Enterprise Value$414.73M

Total Cash (Recent Filing)$836.88M

Total Debt (Recent Filing)$7.59M

Price to Earnings (P/E)―

Beta1.03

Next Earnings

Nov 12, 2025

EPS Estimate

-0.37

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.36

Shares Outstanding57,597,940

10 Day Avg. Volume1,635,443

30 Day Avg. Volume1,119,060

Financial Highlights & Ratios

PEG Ratio3.15

Price to Book (P/B)1.65

Price to Sales (P/S)0.00

P/FCF Ratio-12.11

Enterprise Value/Market Cap0.36

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-1.79K

Enterprise Value/Ebitda-2.29

Forecast

1Y Price Target

$69.20

Price Target Upside217.58% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering12

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentStructure Therapeutics is approaching Phase IIb data from its ACCESS and ACCESS-2 studies with aleniglipron, which is considered a substantial catalyst for the company.

Competitive DifferentiationNo fasting requirement for Structure’s oral small molecule differentiates it from competitors and enhances patient adherence.

Market OpportunityStrong patient demand for a convenient oral option suggests a significant market opportunity for Structure's product.

Bears Say

Investment SentimentRecent obesity data from Lilly's orfoglipron Phase 3 study were received poorly by investors, leading to a significant drop in market cap.

Market CompetitionThe price target was lowered from $60 to $44, driven by reducing the terminal growth rate due to the risk of greater oral competition.

Structure Therapeutics, Inc. Sponsored ADR News

Optimistic Buy Rating for Structure Therapeutics Driven by Aleniglipron’s Potential in Obesity and T2D Markets

Analyst Patrick Dolezal of LifeSci Capital maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR, with a...

10d ago

GPCR

Structure Therapeutics price target lowered to $90 from $92 at Guggenheim

Guggenheim lowered the firm’s price target on Structure Therapeutics (GPCR) to $90 from $92 and keeps a Buy...

1M ago

GPCR

Structure Therapeutics price target raised to $75 from $60 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Structure Therapeutics (GPCR) to $75 from $60 and keeps a...

1M ago

LLY

GPCR

Structure Therapeutics price target lowered to $44 from $60 at Leerink

Leerink analyst David Risinger lowered the firm’s price target on Structure Therapeutics (GPCR) to $44 from $60 and...

1M ago

GPCR

Structure Therapeutics price target lowered to $87 from $89 at Citizens JMP

Citizens JMP lowered the firm’s price target on Structure Therapeutics (GPCR) to $87 from $89 and keeps an...

1M ago

GPCR

Structure Therapeutics Reports Q2 2025 Financial Results

Structure Therapeutics, Inc. Sponsored ADR ( ($GPCR) ) has released its Q2 earnings. Here is a breakdown of...

1M ago

GPCR

Promising Developments in Structure Therapeutics’ Clinical Trials Drive Buy Rating

William Blair analyst Andy Hsieh has reiterated their bullish stance on GPCR stock, giving a Buy rating on...

1M ago

GPCR

Structure Therapeutics files automatic mixed securities shelf

17:18 EDT Structure Therapeutics (GPCR) files automatic mixed securities shelf Published first on TheFly – the ultimate source...

1M ago

GPCR

Structure Therapeutics initiated with a Buy at Clear Street

Clear Street analyst Kaveri Pohlman initiated coverage of Structure Therapeutics (GPCR) with a Buy rating and $61 price...

2M ago

GPCR

Structure Therapeutics initiated with Early-Stage Biotech at Goldman Sachs

Goldman Sachs analyst Corinne Johnson started Structure Therapeutics (GPCR) with an Early-Stage Biotech rating. Published first on TheFly...

2M ago

GPCR

Structure Therapeutics Holds 2025 Annual Shareholders Meeting

Structure Therapeutics, Inc. Sponsored ADR ( ($GPCR) ) has shared an update. On June 23, 2025, Structure Therapeutics...

3M ago

GPCR

Structure Therapeutics, Inc.: Catalyst-Rich Outlook and Strategic Preparations Support Buy Rating

Jefferies analyst Roger Song maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR – Research Report)...

3M ago

GPCR

Structure Therapeutics price target raised to $80 from $75 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Structure Therapeutics (GPCR) to $80 from $75 and keeps a...

4M ago

GPCR

Structure Therapeutics, Inc.: Promising Pipeline and Strong Financial Position Drive Buy Rating

Leerink Partners analyst David Risinger has maintained their bullish stance on GPCR stock, giving a Buy rating on...

4M ago

GPCR

GPCR FAQ

What was Structure Therapeutics, Inc. Sponsored ADR’s price range in the past 12 months?

Structure Therapeutics, Inc. Sponsored ADR lowest stock price was $13.22 and its highest was $45.37 in the past 12 months.

What is Structure Therapeutics, Inc. Sponsored ADR’s market cap?

Structure Therapeutics, Inc. Sponsored ADR’s market cap is $1.16B.

When is Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date?

Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date is Nov 12, 2025 which is in 55 days.

How were Structure Therapeutics, Inc. Sponsored ADR’s earnings last quarter?

Structure Therapeutics, Inc. Sponsored ADR released its earnings results on Aug 06, 2025. The company reported -$0.36 earnings per share for the quarter, missing the consensus estimate of -$0.295 by -$0.065.

Is Structure Therapeutics, Inc. Sponsored ADR overvalued?

According to Wall Street analysts Structure Therapeutics, Inc. Sponsored ADR’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Structure Therapeutics, Inc. Sponsored ADR pay dividends?

Structure Therapeutics, Inc. Sponsored ADR does not currently pay dividends.

What is Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate?

Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate is -0.37.

How many shares outstanding does Structure Therapeutics, Inc. Sponsored ADR have?

Structure Therapeutics, Inc. Sponsored ADR has 57,597,940 shares outstanding.

What happened to Structure Therapeutics, Inc. Sponsored ADR’s price movement after its last earnings report?

Structure Therapeutics, Inc. Sponsored ADR reported an EPS of -$0.36 in its last earnings report, missing expectations of -$0.295. Following the earnings report the stock price went down -0.674%.

Which hedge fund is a major shareholder of Structure Therapeutics, Inc. Sponsored ADR?

Currently, no hedge funds are holding shares in GPCR

Structure Therapeutics, Inc. Sponsored ADR Stock Smart Score

Outperform

Fundamentals

Return on Equity

-21.19%

Trailing 12-Months

Asset Growth

-13.79%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Structure Therapeutics, Inc. Sponsored ADR

Structure Therapeutics, Inc. Sponsored ADR (GPCR) is a biopharmaceutical company focused on discovering and developing innovative treatments for patients with unmet medical needs. The company primarily operates within the healthcare sector, specializing in the development of novel drug candidates targeting G protein-coupled receptors (GPCRs), which play a crucial role in various physiological processes and diseases. Structure Therapeutics leverages advanced technologies and scientific expertise to design and develop therapeutic compounds aimed at addressing conditions such as metabolic disorders, inflammation, and other significant health challenges.

Structure Therapeutics, Inc. Sponsored ADR (GPCR) Earnings & Revenues

Historic Earnings Reports

GPCR Stock 12 Month Forecast

Average Price Target

$69.20

▲(217.58% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","101":"$101","35.75":"$35.8","57.5":"$57.5","79.25":"$79.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":69.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$69.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":44,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$44.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,35.75,57.5,79.25,101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.08,26.22769230769231,32.37538461538462,38.52307692307692,44.67076923076923,50.81846153846154,56.966153846153844,63.113846153846154,69.26153846153846,75.40923076923077,81.55692307692308,87.7046153846154,93.85230769230769,{"y":100,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.08,23.858461538461537,27.636923076923075,31.415384615384617,35.19384615384615,38.972307692307695,42.75076923076924,46.52923076923077,50.30769230769231,54.08615384615385,57.86461538461539,61.643076923076926,65.42153846153846,{"y":69.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.08,21.919999999999998,23.759999999999998,25.599999999999998,27.439999999999998,29.28,31.119999999999997,32.96,34.8,36.64,38.480000000000004,40.32,42.16,{"y":44,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":38.13,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.19,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.14,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.94,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.12,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.97,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.75,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.79,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.33,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.79,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.51,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.59,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.08,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >